lifestyle.digitaladblog.com

Author: Orion Oyj

Orion Pharma initiates TEADCO Phase 1b/2 basket trial evaluating ODM-212 in combination with standard of care treatments in patients with select advanced solid tumours

April 23, 2026
Orion Pharma’s ODM-212 Granted Orphan Drug Designation in Mesothelioma by the US FDA

April 20, 2026
Change in Orion Group Executive Team as of 8 April 2026 – Berkeley Vincent appointed Executive Vice President, Innovative Medicines

April 1, 2026